LAUSD Spent $6M Locking Away Phones—Teens Still Can’t Focus

Los Angeles Unified shelled out more than $6 million to lock up students’ cellphones — but more than half of its high schoolers say...
HomeUSBayer to Pay $7.25 Billion to Settle Weed Killer Cancer Claims

Bayer to Pay $7.25 Billion to Settle Weed Killer Cancer Claims

Agrochemical giant Bayer will pay as much as $7.25 billion over the next two decades to settle thousands of claims from U.S. cancer patients who say the company should have warned that its widely used Roundup weed killer could cause lymphoma. A Missouri judge approved the settlement Friday.

The nationwide agreement covers both current Roundup users who have been diagnosed with non-Hodgkin lymphoma and people who develop the disease in the future. Depending on factors including how they used the product, their age at diagnosis and the seriousness of their illness, participants could receive average payments ranging from $10,000 to $165,000.

Bayer, which is headquartered in Germany and denies that Roundup causes cancer, gains some financial predictability from the deal after years of mounting litigation expenses. The legal costs have prompted the company to consider withdrawing Roundup from U.S. agricultural markets. Bayer has already reformulated the residential version of the product.

The settlement also gives plaintiffs a measure of certainty after a major legal setback. While the agreement was under consideration, the U.S. Supreme Court weakened a central argument in the lawsuits. In June, the court ruled that Bayer could not be sued in state courts over an alleged failure to provide a cancer warning because federal regulations do not require such a label and prevent states from imposing additional labeling rules.

Some lawyers representing cancer patients argue that the payouts are inadequate. Others say the agreement is preferable to receiving nothing, a result that became more likely after the Supreme Court’s decision.

In a written ruling approving the agreement, St. Louis Circuit Judge Timothy Boyer described the average payments as “fair and adequate.” He also called the total settlement value “among the largest in the history of mass tort personal-injury class action settlements.” The deal includes $600 million for attorneys’ fees.

Boyer said Bayer might have sought bankruptcy protection if the settlement had been rejected.

Bayer CEO Bill Anderson said the approval represented “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”

The ruling may still be appealed.

Roundup has been used on weeds for over 50 years

Missouri-based Monsanto introduced Roundup in 1974, using glyphosate as its active ingredient. The herbicide quickly became one of agriculture’s most widely used weed killers. It is designed to work with genetically modified seeds that are resistant to glyphosate, allowing farmers to increase production while reducing soil disruption through less tilling.

Roundup is also widely used on household lawns and gardens.

Bayer acquired Roundup as part of its purchase of Monsanto in 2018. The transaction also brought a growing number of lawsuits alleging that glyphosate causes non-Hodgkin lymphoma, although the issue remains contested. The World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic” in 2015. The U.S. Environmental Protection Agency, however, has concluded that the chemical is unlikely to cause cancer in humans when used according to instructions.

Roughly 200,000 claims related to Roundup have been filed against Bayer, many by people who used the product around their homes. In response, Bayer removed glyphosate from newer Roundup products marketed for residential use.

The litigation has produced conflicting outcomes. Only a few dozen cases have reached juries, with some verdicts favoring Bayer and others siding with plaintiffs. In one case, a Georgia jury awarded plaintiffs $2.1 billion.

In the first Roundup verdict after the Supreme Court’s landmark ruling, a Missouri jury sided with Bayer in October. The case involved allegations of design defects, negligence and fraud. The verdict “should send a strong signal” that plaintiffs “will face significant challenges” in future Roundup cancer cases, said Bill Dodero, Bayer’s U.S. general counsel and global litigation leader.

Attorneys disagree on whether the settlement is fair

Bayer had previously reserved $16 billion for legal expenses tied to Roundup litigation. The new agreement is separate from that amount and is intended to resolve most outstanding lawsuits, along with future claims from people exposed to Roundup before the settlement was proposed in February.

“Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice,” said Christopher A. Seeger, court-appointed counsel for the cancer patients.

Under the agreement, Bayer will make yearly contributions to a dedicated fund for as many as 21 years, with total payments reaching up to $7.25 billion. Individual awards will vary. Agricultural, industrial and turf workers who had prolonged exposure and were diagnosed with an aggressive form of the disease before age 60 could receive an average of $165,000. Claimants diagnosed at age 78 or older would receive considerably less, averaging $10,000.

Some lawyers have criticized the individual awards as too low and the settlement’s conditions as overly restrictive.

“This settlement is the scariest, worst future settlement that’s ever been contemplated,” attorney Gerson Smoger said at a September hearing on the agreement. He argued that it bound future claimants for decades, eliminated the possibility of punitive damages and left the product on the market, “allowing the victims to continue to be exposed.”

The agreement was filed in St. Louis Circuit Court in Missouri, where Bayer’s North America crop science division is based and where many of the lawsuits have been filed.